Clinical Trials · NCT03929744

A Study of LY3502970 in Healthy Participants

CompletedPhase 1Orforglipron (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
133
Start date
Jun 2019
Locations
1 site, United States
Primary endpoint
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
View Orforglipron compound reference